Physical and catalytic properties of a peroxidase derived from cytochrome c

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 9, 2011, Pages 1138-1145

  Everse, Johannes ^a   Liu, Chyong Jy J ^a   Coates, Penelope W ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cellular metabolites; Cytochrome c; Cytolysis; Neurodegeneration; Parkinson's disease; Peroxidase

Indexed keywords

COENZYME A; CYTOCHROME C; DOPAMINE; HYDROGEN PEROXIDE; LACTOPEROXIDASE; MYELOPEROXIDASE; PEROXIDASE; THIOL DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOLYSIS; CYTOSOL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME MECHANISM; IN VIVO STUDY; NERVE CELL; NONHUMAN; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTIOXIDANTS; CYTOCHROMES C; DOPAMINE; HUMANS; PARKINSON DISEASE; PEROXIDASES;

ARMORACIA RUSTICANA; PARKINSONIA;

EID: 79960565354     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.05.003     Document Type: Article

References (68)

1. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 1976, 38:277-301.
2. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
3. Everse J., Coates P.W. Neurodegeneration and peroxidases. Neurobiol. Aging 2009, 30:1011-1025.
4. Burkitt M.J., Wardman P. Cytochrome c is a potent catalyst of dichlorofluorescin oxidation: implications for the role of reactive oxygen species in apoptosis. Biochem. Biophys. Res. Commun. 2001, 282:329-333.
5. Grisham M.B., Perez V.J., Everse J. Neuromelanogenic and cytotoxic properties of canine brainstem peroxidase. J. Neurochem. 1987, 48:876-882.
6. Galzigna L., Schiappelli M.P., Rigo A., Scarpa M. A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochim. Biophys. Acta 1999, 1427:329-336.
7. Galzigna L., De Iuliis A., Zanatta L. Enzymatic dopamine peroxidation in substantia nigra of human brain. Clin. Chim. Acta 2000, 300:131-138.
8. De Iuliis A., Burlina A.P., Boschetto R., Zambenedetti P., Arslan P., Galzigna L. Increased dopamine peroxidation in postmortem Parkinsonian brain. Biochim. Biophys. Acta 2002, 1573:63-67.
9. De Iuliis A., Arrigoni G., Andersson L., Zambenedetti P., Burlina A., James P., Arslan P., Vianello F. Oxidative metabolism of dopamine: a colour reaction from human midbrain analysed by mass spectrometry. Biochim. Biophys. Acta 2008, 1784:1687-1693.
10. Culmsee C., Landshamer S. Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr. Alzheimer Res. 2006, 3:269-283.
11. Niizuma K., Endo H., Chan P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J. Neurochem. 2009, 109(Suppl. 1):133-138.
12. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., Taniguchi T. Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 2001, 417:59-67.
13. Burkitt M., Jones C., Lawrence A., Wardman P. Activation of cytochrome c to a peroxidase compound I-type intermediate by H2O2: relevance to redox signalling in apoptosis. Biochem. Soc. Symp. 2004, 71:97-106.
14. Harbury H.A., Loach P.A. Oxidation-linked protein functions in heme octa- and undecapeptides from mammalian cytochrome c. J. Biol. Chem. 1960, 235:3640-3645.
15. Marques H.M. Insights into porphyrin chemistry provided by the microperoxidase, the haempeptides derived from cytochrome c. Dalton Trans. 2007, 39:4371-4385.
16. Lin H., McFaul S.J., Brady J.C., Everse J. The mechanism of peroxidase-mediated cytotoxicity. II. Role of the heme moiety. Proc. Soc. Exptl. Biol. Med. 1988, 187:7-13.
17. Everse J., Coates P.W. Role of peroxidases in Parkinson's disease: a hypothesis. Free Rad. Biol. Med. 2005, 38:1295-1309.
18. Hildebraunt A.G., Roots I. Reduced NADPH-dependent formation and breakdown of hydrogen peroxide during mixed function oxidation reactions in liver microsomes. Arch. Biochem. Biophys. 1975, 171:385-397.
19. Claiborne A., Fridovich I. Purification of the o-dianisidine peroxidase from Escherichia coli B. J. Biol. Chem. 1979, 254:4245-4252.
20. Wright S.K., Viola R.E. Evaluation of methods for the quantitation of cysteines in proteins. Anal. Biochem. 1998, 265:8-14.
21. McFaul S.J., Everse J. A continuous assay for the measurement of cytolytic activity. Methods in Enzymology 1986, Vol. 132:491-498. Academic Press, San Diego. G. DiSabato, J. Everse (Eds.).
22. McFaul S.J., Lin H., Everse J. The mechanism of peroxidase-mediated cytotoxicity. I. Comparison of horseradish peroxidase and lactoperoxidase. Proc. Soc. Exptl. Biol. Med. 1986, 183:244-249.
23. McFaul S.J., Stuyt E.L., Everse J. Observations on cytolytic activity of lactoperoxidase using a continuous assay. Proc. Soc. Exptl. Biol. Med. 1985, 179:331-337.
24. Everse J., Johnson M.C., Marini M. Peroxidative activities of hemoglobin and hemoglobin derivatives. Methods in Enzymology 1994, Vol. 231:547-561. Academic Press, San Diego.
25. Aron J., Baldwin D.A., Marques H.M., Pratt J.M., Adams P.A. Hemes and hemeproteins. 1. Preparation and analysis of the heme-containing octapeptide (microperoxidase-8) and identification of the monomeric form in aqueous solution. J. Inorg. Biochem. 1986, 27:227-243.
26. Adams P.A. Microperoxidases and iron porphyrins. Peroxidases in Chemistry and Biology 1991, Vol. II:171-200. CRC Press, Boca Raton FL.
27. Jagatha B., Mythri R.B., Vali S., Bharath M.M. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Rad. Biol. Med. 2008, 44:907-917.
28. Beal M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(suppl. 3):S189-S194.
29. Balmiki R., Lahiri D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol. 2009, 9:434-444.
30. Hamaguchi T., Ono K., Yamada M. Curcumin and Alzheimer's disease. CNS Neurosci. Ther. 2010, 16:285-297.
31. Klebanoff S.J. Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J. Bacteriol. 1968, 95:2131-2138.
32. Clark R.A., Klebanoff S.J., Einstein A.B., Fefer A. Peroxidase-H2O2-halide system: cytotoxic effect on mammalian tumor cells. Blood 1975, 45:161-170.
33. Lin H., Everse J. The cytotoxic activity of hematoheme: evidence for two different mechanisms. Anal. Biochem. 1987, 161:323-331.
34. Radi R., Turrens J.F., Freeman B.A. Cytochrome C-catalyzed membrane lipid peroxidation by hydrogen peroxide. Arch. Biochem. Biophys. 1991, 288:118-125.
35. Kim N.H., Jeong M.S., Choi S.Y., Kang J.H. Oxidative modification of cytochrome c by hydrogen peroxide. Mol. Cells 2006, 22:220-227.
36. Jang B., Han S. Biochemical properties of cytochrome C nitrated by peroxynitrite. Biochimie 2006, 88:53-58.
37. Lawrence A., Jones C.M., Wardman P., Burkitt M.J. Evidence for the role of a peroxidase compound I-type intermediate in the oxidation of glutathione, NADH, ascorbate, and dichlorofluorescin by cytochrome c/H2O2. Implications for oxidative stress during apoptosis. J. Biol. Chem. 2003, 278:29410-29419.
38. Jiang J., Kini V., Belikova N., Serinkan B.F., Borisenko G.G., Tyurina Y.Y., Tyurin V.A., Kagan V.E. Cytochrome c release is required for phosphatidylserine peroxidation during Fas-triggered apoptosis in lung epithelial A549 cells. Lipids 2004, 39:1133-1142.
39. Kagan V.E., Tyurin V.A., Jiang J., Ritov V.B., Amoscato A.A., Osipov A.N., Belikova N.A., Kapralov N.A., Kini J., Vlasova I.I., Zhao Q., Zou M., Di P., Svistanenko D.A., Karnikov I.V., Borisenko G.G. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat. Chem. Biol. 2005, 1:223-232.
40. Belikova N.A., Vladimirov Y.A., Osipov A.N., Kapralov A.A., Tyurin V.A., Potapovich M.V., Basova L.V., Peterson J., Kurnikov I.V., Kagan V.E. Peroxidase activity and structural transitions of cytochrome c bound to cardiolipin-containing membranes. Biochemistry 2006, 45:4998-5009.
41. Godoy L.C., Munoz-Pinedo C., Castro L., Cardaci S., Schonhoff C.M., King M., Tortora V., Marin M., Miao Q., Jiang J.F., Kapralov A., Jemmerson R., Silkstone G.G., Patel J.N., Evans J.E., Wilson M.T., Green D.R., Kagan V.E., Radi R., Mannick J.B. Disruption of the M80-Fe ligation stimulates the translocation of cytochrome c to the cytoplasm and nucleus of nonapoptotic cells. Proc. Natl. Acad. Sci. USA 2009, 106:2653-2658.
42. Mizuta T., Shimizu S., Matsuoka Y., Nakagawa T., Tsujimoto Y. A Bax/Bak-independent mechanism of cytochrome c release. J. Biol. Chem. 2007, 282:16623-16630.
43. Klebanoff S.J. Myeloperoxidase; occurrence and biological function. Peroxidases in Chemistry and Biology 1991, Vol. I:1-35. CRC Press, Boca Raton FL.
44. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 1980, 102:344-352.
45. Cadenas E., Davies K.J.A. Mitochondrial free radical generation, oxidative stress, and aging. Free Rad. Biol. Med. 2000, 29:222-230.
46. Hsu M., Srinivas B., Kumar J., Subramanian R., Andersen J. Glutathione depletion resulting in selective mitochondrial Complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J. Neurochem. 2005, 92:1091-1103.
47. Harish G., Venkateshappa C., Mythri R.B., Dubey S.K., Mishra K., Singh N., Vali S., Bharath M.M.S. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: implications for Parkinson's disease. Bioorg. Med. Chem. 2010, 18:2631-2638.
48. Owen J.B., Butterfield D.A. Measurement of oxidized/reduced glutathione ratio. Methods Mol. Biol. 2010, 648:269-277.
49. Bowen B.C., Block R.E., Ramos-Sanchez J., Patteny P.M., Lampman D.A., Murdoch J.B., Quencer R.M. Proton MR spectroscopy of the brain in 14 patients with Parkinson's disease. Am. J. Neuroradiol. 1995, 16:61-68.
50. Podell M., Hadjiconstantinou M., Smith M.A., Neff N.H. Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. Exp. Neurol. 2003, 179:159-166.
51. Koga K., Mori A., Ohashi S., Kurihara N., Kitagawa H., Ishikawa M., Mitsumoto Y., Nakai M. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur. J. Neurosci. 2006, 23:1077-1081.
52. Huang X., Abbott R.D., Petrovitch H., Mailman R.B., Ross G.W. Low LDL-cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging study. Mov. Disord. 2008, 23:1013-1018.
53. Yeger-Lotem E., Riva L., Su I.J., Gitler A.D., Cashikar A.G., King O.D., Auluck P.K., Geddie M.L., Valastyan J.S., Karger D.R., Lindquist S., Fraenkel E. Bridging high-throughput genetic and transcriptional data reveals cellular responses to α-synuclein toxicity. Nat. Genet. 2009, 41:316-323.
54. Van Woert M.H., Mueller P.S. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levo-DOPA. Clin. Pharmacol. Ther. 1971, 12:360-367.
55. Riekkinen P., Rinne U.K., Pelliniemi T.T., Sonninen V. Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson's disease patients. Arch. Neurol. 1975, 32:25-27.
56. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994, 9:92-97.
57. Isacson O. Models of repair mechanisms for future treatment modalities of Parkinson's disease. Brain Res. Bull. 2002, 57:839-846.
58. Oyagi A., Oida Y., Hara H., Izuta H., Shimazawa M., Matsunaga N., Adachi T., Hara H. Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. Brain Res. 2008, 1214:169-176.
59. Auluck P.K., Caraveo G., Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 2010, 26:211-233.
60. Su I.J., Auluck P.K., Outeiro T.F., Yeger-Lotem E., Kritzer J.A., Tardiff D.F., Strathearn K.E., Liu F., Cao S., Hamamichi S., Hill K.J., Caldwell K.A., Bell G.W., Fraenkel E., Cooper A.A., Caldwell G.A., McCaffery J.M., Rochet J.C., Lindquist S. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis. Model. Mech. 2010, 3:194-208.
61. Atamna H., Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103:3381-3386.
62. Atamna H. Amino acid variations in amyloid-β peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease. J. Bioenerg. Biomembr. 2009, 41:457-464.
63. Atamna H., Frey W.H., Ko N. Human and rodent amyloid-β peptides differentially bind heme: relevance to the human susceptibility to Alzheimer's disease. Arch. Biochem. Biophys. 2009, 487:59-65.
64. Hodgson E.K., Fridovich I. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme. Biochemistry 1975, 24:5294-5299.
65. Zhang H., Joseph J., Gurney M., Becker D., Kalyanaraman B. Bicarbonate enhances peroxidase activity of Cu, Zn-superoxide dismutase. Role of carbonate anion radical and scavenging of carbonate anion radical by metalloporphyrin antioxidant enzyme mimetics. J. Biol. Chem. 2002, 277:1013-1020.
66. Zhang H., Andrekopoulos C., Joseph J., Chandran K., Karoui H., Crow J.P., Kalyanaraman B. Bicarbonate-dependent peroxidase activity of human Cu, Zn-superoxide dismutase induces covalent aggregation of protein: intermediacy of tryptophan-derived oxidation products. J. Biol. Chem. 2003, 278:193-197.
67. Barbosa L.F., Cerqueira F.M., Macedo A.F.A., Garcia C.C.M., Angeli J.P.F., Schumacher R.I., Sogayar M.C., Augusto O., Carri M.T., Di Mascio P., Medeiros M.H.G. Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS. Biochim. Biophys. Acta 2010, 1802:462-471.
68. Dickerson R.E., Takano T., Eisenberg D., Kallai O.B., Samson L., Cooper A., Margoliash E. Ferricytochrome c. I. General features of the horse and bonito proteins at 2.8Å resolution. J. Biol. Chem. 1971, 246:1511-1535.